Journal
CANCER INVESTIGATION
Volume 39, Issue 8, Pages 627-644Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07357907.2021.1952595
Keywords
Glioma stem cells; temozolomide; drug resistance; glioblastoma; targeted therapy
Categories
Funding
- Natural Science Foundation of Beijing Municipality [Z190018]
- National Natural Science Foundation of China [81870123]
- National Science Foundation for Young Scientists of China [81902545]
Ask authors/readers for more resources
This review discusses the impact of glioma stem cells (GSCs) on TMZ resistance in Glioblastoma (GB) and potential therapies, aiming to improve treatment efficacy.
Glioblastoma (GB) is the most lethal form of primary brain neoplasm. TMZ is the first-line standard treatment, but the strong resistance constrains the efficacy in clinical use. GB contains glioma stem cells (GSCs), which contribute to TMZ resistance, promote cell survival evolvement, and repopulate the tumor mass. This review summarizes the TMZ-resistance mechanisms and discusses several potential therapies from the conservative opinion of GSC-targeted therapy orientation to the current view of TMZ resistance-aimed efficacy, which will provide an understanding of the role of heterogeneity in drug resistance and improve therapeutic efficacy in general.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
